| Product Code: ETC7623288 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary  | 
2 Introduction  | 
2.1 Key Highlights of the Report  | 
2.2 Report Description  | 
2.3 Market Scope & Segmentation  | 
2.4 Research Methodology  | 
2.5 Assumptions  | 
3 Ireland Antimicrobial Resistance Market Overview  | 
3.1 Ireland Country Macro Economic Indicators  | 
3.2 Ireland Antimicrobial Resistance Market Revenues & Volume, 2021 & 2031F  | 
3.3 Ireland Antimicrobial Resistance Market - Industry Life Cycle  | 
3.4 Ireland Antimicrobial Resistance Market - Porter's Five Forces  | 
3.5 Ireland Antimicrobial Resistance Market Revenues & Volume Share, By Indication, 2021 & 2031F  | 
3.6 Ireland Antimicrobial Resistance Market Revenues & Volume Share, By Drug Class, 2021 & 2031F  | 
3.7 Ireland Antimicrobial Resistance Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F  | 
3.8 Ireland Antimicrobial Resistance Market Revenues & Volume Share, By Pathogen, 2021 & 2031F  | 
4 Ireland Antimicrobial Resistance Market Dynamics  | 
4.1 Impact Analysis  | 
4.2 Market Drivers  | 
4.2.1 Increasing prevalence of infectious diseases in Ireland  | 
4.2.2 Growing awareness about the impact of antimicrobial resistance on public health  | 
4.2.3 Investments in research and development for new antimicrobial drugs  | 
4.3 Market Restraints  | 
4.3.1 Strict regulatory environment for antimicrobial drugs  | 
4.3.2 Lack of effective antibiotic stewardship programs  | 
4.3.3 Limited availability of new treatment options for resistant infections  | 
5 Ireland Antimicrobial Resistance Market Trends  | 
6 Ireland Antimicrobial Resistance Market, By Types  | 
6.1 Ireland Antimicrobial Resistance Market, By Indication  | 
6.1.1 Overview and Analysis  | 
6.1.2 Ireland Antimicrobial Resistance Market Revenues & Volume, By Indication, 2021- 2031F  | 
6.1.3 Ireland Antimicrobial Resistance Market Revenues & Volume, By Complicated Urinary Tract Infections (cUTI), 2021- 2031F  | 
6.1.4 Ireland Antimicrobial Resistance Market Revenues & Volume, By Blood stream infections, 2021- 2031F  | 
6.1.5 Ireland Antimicrobial Resistance Market Revenues & Volume, By Acute bacterial skin and skin structure infections (ABSSSI), 2021- 2031F  | 
6.1.6 Ireland Antimicrobial Resistance Market Revenues & Volume, By Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), 2021- 2031F  | 
6.1.7 Ireland Antimicrobial Resistance Market Revenues & Volume, By Community acquired pneumonia (CAP), 2021- 2031F  | 
6.1.8 Ireland Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F  | 
6.2 Ireland Antimicrobial Resistance Market, By Drug Class  | 
6.2.1 Overview and Analysis  | 
6.2.2 Ireland Antimicrobial Resistance Market Revenues & Volume, By Combination therapies, 2021- 2031F  | 
6.2.3 Ireland Antimicrobial Resistance Market Revenues & Volume, By Tetracyclines, 2021- 2031F  | 
6.2.4 Ireland Antimicrobial Resistance Market Revenues & Volume, By Cephalosporins, 2021- 2031F  | 
6.2.5 Ireland Antimicrobial Resistance Market Revenues & Volume, By Glycopeptides and Lipoglycopeptides, 2021- 2031F  | 
6.2.6 Ireland Antimicrobial Resistance Market Revenues & Volume, By Oxazolidinones, 2021- 2031F  | 
6.2.7 Ireland Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F  | 
6.3 Ireland Antimicrobial Resistance Market, By Mechanism of Action  | 
6.3.1 Overview and Analysis  | 
6.3.2 Ireland Antimicrobial Resistance Market Revenues & Volume, By Protein Synthesis Inhibitors, 2021- 2031F  | 
6.3.3 Ireland Antimicrobial Resistance Market Revenues & Volume, By Cell Wall Synthesis Inhibitors, 2021- 2031F  | 
6.3.4 Ireland Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F  | 
6.4 Ireland Antimicrobial Resistance Market, By Pathogen  | 
6.4.1 Overview and Analysis  | 
6.4.2 Ireland Antimicrobial Resistance Market Revenues & Volume, By Klebsiella pneumoniae, 2021- 2031F  | 
6.4.3 Ireland Antimicrobial Resistance Market Revenues & Volume, By Pseudomonas aeruginosa, 2021- 2031F  | 
6.4.4 Ireland Antimicrobial Resistance Market Revenues & Volume, By Staphylococcus aureus, 2021- 2031F  | 
6.4.5 Ireland Antimicrobial Resistance Market Revenues & Volume, By Enterococcus Spp, 2021- 2031F  | 
6.4.6 Ireland Antimicrobial Resistance Market Revenues & Volume, By Escherichia coli, 2021- 2031F  | 
6.4.7 Ireland Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F  | 
7 Ireland Antimicrobial Resistance Market Import-Export Trade Statistics  | 
7.1 Ireland Antimicrobial Resistance Market Export to Major Countries  | 
7.2 Ireland Antimicrobial Resistance Market Imports from Major Countries  | 
8 Ireland Antimicrobial Resistance Market Key Performance Indicators  | 
8.1 Rate of antimicrobial-resistant infections in Ireland  | 
8.2 Percentage of healthcare facilities implementing antimicrobial stewardship programs  | 
8.3 Number of new antimicrobial drugs in development in Ireland  | 
9 Ireland Antimicrobial Resistance Market - Opportunity Assessment  | 
9.1 Ireland Antimicrobial Resistance Market Opportunity Assessment, By Indication, 2021 & 2031F  | 
9.2 Ireland Antimicrobial Resistance Market Opportunity Assessment, By Drug Class, 2021 & 2031F  | 
9.3 Ireland Antimicrobial Resistance Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F  | 
9.4 Ireland Antimicrobial Resistance Market Opportunity Assessment, By Pathogen, 2021 & 2031F  | 
10 Ireland Antimicrobial Resistance Market - Competitive Landscape  | 
10.1 Ireland Antimicrobial Resistance Market Revenue Share, By Companies, 2024  | 
10.2 Ireland Antimicrobial Resistance Market Competitive Benchmarking, By Operating and Technical Parameters  | 
11 Company Profiles  | 
12 Recommendations  | 
13 Disclaimer  |